Literature DB >> 15064759

Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance.

Yiping Yang1, Ching-Tai Huang, Xiaopei Huang, Drew M Pardoll.   

Abstract

One chief barrier to cancer immunotherapy is tumor-specific T cell tolerance. Here we compared the ability of hemagglutinin (HA)-encoding recombinant viruses versus 'HA-loaded' dendritic cells to reverse HA-specific CD8 tolerance and to protect mice from tumor challenge. Both vaccines were comparable in activating naive HA-specific CD8(+) T cells. However, in circumstances of established tolerance, viral vaccines could break CD8 tolerance in the presence of CD4(+)CD25(+) regulatory T cells, whereas dendritic cell-based vaccines achieved this only after removal of regulatory T cells or the coadministration of a Toll-like receptor (TLR) ligand or irrelevant virus. These results demonstrate that virus provides TLR signals required for bypassing regulatory T cell-mediated tolerance and emphasize the importance of persistent TLR signals for immunotherapy in the setting of established tolerance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15064759     DOI: 10.1038/ni1059

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  131 in total

1.  Microbial infection-induced expansion of effector T cells overcomes the suppressive effects of regulatory T cells via an IL-2 deprivation mechanism.

Authors:  Alicia Benson; Sean Murray; Prashanthi Divakar; Nikolay Burnaevskiy; Reed Pifer; James Forman; Felix Yarovinsky
Journal:  J Immunol       Date:  2011-12-05       Impact factor: 5.422

2.  NKG2D is required for NK cell activation and function in response to E1-deleted adenovirus.

Authors:  Jiangao Zhu; Xiaopei Huang; Yiping Yang
Journal:  J Immunol       Date:  2010-11-12       Impact factor: 5.422

3.  Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta.

Authors:  Jiangao Zhu; Jennifer Martinez; Xiaopei Huang; Yiping Yang
Journal:  Blood       Date:  2006-09-14       Impact factor: 22.113

4.  Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice.

Authors:  Timothy P Moran; Joseph E Burgents; Brian Long; Ivana Ferrer; Elizabeth M Jaffee; Roland M Tisch; Robert E Johnston; Jonathan S Serody
Journal:  Vaccine       Date:  2007-07-17       Impact factor: 3.641

5.  Innate signals compensate for the absence of PKC-{theta} during in vivo CD8(+) T cell effector and memory responses.

Authors:  Benjamin J Marsland; Chiara Nembrini; Nicole Schmitz; Brian Abel; Stefan Krautwald; Martin F Bachmann; Manfred Kopf
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-26       Impact factor: 11.205

6.  Enhancement of humoral immune responses to HBsAg by heat shock protein gp96 and its N-terminal fragment in mice.

Authors:  Hong-Tao Li; Jia-Bin Yan; Jing Li; Ming-Hai Zhou; Xiao-Dong Zhu; Yu-Xia Zhang; Po Tien
Journal:  World J Gastroenterol       Date:  2005-05-21       Impact factor: 5.742

7.  SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling.

Authors:  Kevin Evel-Kabler; Xiao-Tong Song; Melissa Aldrich; Xue F Huang; Si-Yi Chen
Journal:  J Clin Invest       Date:  2005-12-15       Impact factor: 14.808

8.  CD8+ T-cell dysfunction due to cytolytic granule deficiency in persistent Friend retrovirus infection.

Authors:  Gennadiy Zelinskyy; Shelly J Robertson; Simone Schimmer; Ronald J Messer; Kim J Hasenkrug; Ulf Dittmer
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 9.  Ubiquitous points of control over regulatory T cells.

Authors:  Fan Pan; Joseph Barbi
Journal:  J Mol Med (Berl)       Date:  2014-04-29       Impact factor: 4.599

Review 10.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.